Summary:
A Phase 1B, open label, dose finding study of an investigational medication administered orally to patients with primary myelofibrosis with low platelets.
Qualified Participants Must:
• Be 18 years of age or older
•
Have a diagnosis of Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia-Myelofibrosis
•
Have baseline platelet counts ≥ 50K and <100K
Qualified Participants May Receive:
All study related medication and care at no cost. There is no compensation for the study, although there may be reimbursement for travel expenses.